目的 比较比索洛尔和低分子肝素治疗老年不稳定心绞痛的临床疗效和安全性。方法 选取2011年9月-2013年4月在延安市中医医院就诊的不稳定心绞痛患者186例，随机分为比索洛尔组、低分子肝素组和对照组，每组62例。对照组给予吸氧、阿司匹林、硝酸甘油治疗，比索洛尔组在对照组的基础上口服比索洛尔片，5 mg/次，1次/d；低分子肝素组在对照组的基础上加用低分子肝素注射液，皮下注射，0.6 mL/次，2次/d。3组均连续治疗2个月。治疗后，比较3组患者的临床疗效和心血管事件发生率。结果 比索洛尔组、低分子肝素组的临床疗效有效率及心电图改善优良率均较对照组高，均具有统计学意义（P<0.05）；比索洛尔组的临床疗效有效率和心电图改善优良率均高于低分子肝素组，两组比较差异均有统计学意义（P<0.05）。比索洛尔组、低分子肝素组的心绞痛、心律失常、急性心肌梗死发生率均低于对照组，差异有统计学意义（P<0.05）；比索洛尔组和低分子肝素组心绞痛、心律失常、急性心肌梗死的发生率差异没有统计学意义。3组不良反应发生率比较，差异均不具有统计学意义。结论 在常规治疗基础上给予比索洛尔治疗不稳定心绞痛具有确切的临床疗效，不良反应较少，值得临床推广应用。

Objective To compare the clinical efficacy and safety between bisoprolol and low molecular heparin in the treatment of elderly unstable angina. Methods Unstable angina patients (186 cases) who came to Hospital of Traditional Chinese Medicine in Yan'an City from September 2011 to April 2013 were randomly divided into bisoprolol, low molecular heparin, and control groups, and each group had 62 cases. The patients in the treatment group were given oxygen, aspirin, and nitroglycerin. The patients in the bisoprolol group were po administered with Bisoprolol Tablets, 5 mg/time, once daily on the basis of the control group. The patients in the low molecular heparin group weresc administered with Low Molecular Heparin Injecion, 0.6 mL/time, twice daily, and other treatment was the same as the control group. The patients in three groups were treated for two months. After treatment, the clinical efficacy and incidence of cardiovascular events were compared in the three groups. Results The clinical effect and electrocardiogram improved rate in bisoprolol and low molecular heparin groups were higher than those in the control group with the significant difference (P < 0.05). The clinical effect and electrocardiogram improved rate in bisoprolol group were higher than those in the low molecular heparin group, with significant difference between the two groups (P < 0.05). The incidence of angina pectoris, arrhythmia, and acute myocardial infarction in bisoprolol and low molecular heparin groups were lower than those in the control group with the significant difference (P < 0.05). There was no significant difference between bisoprolol and low molecular heparin groups in the incidence of angina pectoris, arrhythmia, and acute myocardial infarction. Incidence of adverse reactions had no statistically significant differences in three groups. Conclusion Bisoprolol on the basis of conventional treatment has a good clinical efficacy in the treatment of unstable angina with exact clinical curative effect and less adverse reaction, which is worthy of clinical popularization and application.